ACELRX PHARMACEUTICALS WKN: A1H64B ISIN: US00444T1007 Kürzel: R5X Forum: Aktien Thema: Hauptdiskussion

Next push

...gutes Volumen heute...

AcelRx Pharmaceuticals Provides Update on Reduced FDA REMS Requirements Related to DSUVIA® https://www.biospace.com/article/releases/acelrx-pharmaceuticals-provides-update-on-reduced-fda-rems-requirements-related-to-dsuvia-/

https://www.prnewswire.com/news-releases/acelrx-pharmaceuticals-reports-first-quarter-2022-financial-results-and-provides-corporate-update-301547773.html AcelRx Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update

https://www.prnewswire.com/news-releases/acelrx-pharmaceuticals-announces-publication-of-results-from-an-investigator-initiated-trial-on-sufentanil-sublingual-tablet-sst-compared-to-standard-intravenous-opioids-during-plastic-surgery-procedures-performed-under-general--301543161.html

Denke die Bude wird Insolvenz anmelden Das wird nichts mehr

AcelRx Pharmaceuticals Announces Publication of Results from a Clinical Study Assessing Use of Sufentanil Sublingual Tablet for Painful Radiofrequency Microneedling Procedures https://www.prnewswire.com/news-releases/acelrx-pharmaceuticals-announces-publication-of-results-from-a-clinical-study-assessing-use-of-sufentanil-sublingual-tablet-for-painful-radiofrequency-microneedling-procedures-301515290.html Study results show higher rates of successful procedure completion and higher patient and clinician satisfaction scores compared to topical local anesthesia alone

Ja, schwierige Sache hier...

Fällt seit der Zulassung. Übel gelaufen hier. Die kam von über 5$. Hoffe, ich sehe meinen EK je wieder.

Trotzdem fällt sie wie ein Stein Da helfen news auch nichts mehr

AcelRx Pharmaceuticals Announces Publication of Clinical Data Finding Potential Benefits of Nafamostat Compared to Regional Citrate for Anticoagulation of the Dialysis Circuit https://www.prnewswire.com/news-releases/acelrx-pharmaceuticals-announces-publication-of-clinical-data-finding-potential-benefits-of-nafamostat-compared-to-regional-citrate-for-anticoagulation-of-the-dialysis-circuit-301513012.html

Scheiße alles.

AcelRx Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results https://www.prnewswire.com/news-releases/acelrx-pharmaceuticals-reports-fourth-quarter-and-full-year-2021-financial-results-301500455.html AcelRx expanded late-stage pipeline with Niyad™ (nafamostat), which has received Breakthrough Designation status from the FDA and an ICD-10 procedural code from CMS Q4 2021 DSUVIA unit sales growth of 142% compared to Q3 2021 AcelRx had $51.6 million of cash and short-term investments as of December 31, 2021

Ende 2023 können wir ernten

AcelRx Pharmaceuticals Announces Publication of Clinical Data on the Use of Sufentanil Sublingual Tablet during Awake Plastic Surgery Procedures https://finance.yahoo.com/news/acelrx-pharmaceuticals-announces-publication-clinical-133000915.html Study concluded that awake plastic surgery procedures can be performed using sublingual sufentanil tablet (30 mcg) with minimal side effects and a rapid recovery time